GGrantIndex
Sort

50,496 grants matching lung cancer

Leveraging deep learning for markerless motion management in radiation therapy

$411,262
Lei Xing · Stanford University · R01 · FY2024 · CA

Impact of nucleotide metabolism on bacterial clearance

$411,250
Sebastian Alejandro Riquelme Colet · Columbia University Health Sciences · R35 · FY2024 · GM

Impact of nucleotide metabolism on bacterial clearance

$411,250
Sebastian Alejandro Riquelme Colet · Columbia University Health Sciences · R35 · FY2025 · GM

Impact of nucleotide metabolism on bacterial clearance

$411,250
Sebastian Alejandro Riquelme Colet · Columbia University Health Sciences · R35 · FY2023 · GM

Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development

$411,223
Humam Kadara · University Of Tx Md Anderson Can Ctr · U01 · FY2024 · CA

Novel applications and translation of [18F]hGTS13, a system xc- specific radiopharmaceutical

$411,206
Jianghong Rao · Stanford University · R01 · FY2024 · CA

MATCHMAKERS: Solving T-cell receptor recognition and design via integrated high-throughput screening and structural, functional and computational approaches

$411,201
Stephen J Elledge · Brigham And Women'S Hospital · OT2 · FY2025 · CA

Noncovalent interaction of mutant KRAS inhibitors

$411,152
Jen-Tsan Ashley Chi · Duke University · R21 · FY2025 · CA

Inhibition of Radiation-Induced Coronary Microvascular Disease

$411,136
Saraswati Pokharel · Roswell Park Cancer Institute Corp · R01 · FY2025 · HL

Basic Mechanisms in Lung Disease

$411,131
University Of Alabama At Birmingham · T32 · FY2003 · HL

Functional Determinants of Metastatic Dormancy

$411,127
Julio A Aguirre-Ghiso · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · CA

MEK AND PI3K INHIBITION IN THE REGULATION OF PANCREATIC CANCER METABOLISM

$411,122
Lewis C Cantley · University Of Tx Md Anderson Can Ctr · P01 · FY2014 · CA

Organic cation transporter 2 and cisplatin nephrotoxicity

$411,104
Alexander Sparreboom · St. Jude Children'S Research Hospital · R01 · FY2010 · CA

Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers

$411,067
Duke University · U01 · FY2002 · CA

Impact of Direct to Consumer Genetic Testing

$411,045
Robert C. Green · Boston University Medical Campus · R01 · FY2010 · HG

Exploring Statin Pleiotropic Effects within a Very Large EHR Cohort

$410,983
Wei-Qi Wei · Vanderbilt University Medical Center · R01 · FY2019 · HL

Lung Epithelial-Mesenchymal Interactions in Adenocarcinoma Invasion

$410,977
Charles A. Powell · Columbia University Health Sciences · R01 · FY2008 · CA

Project 3: Arsenic Biomarker Epidemiology

$410,861
Allan H Smith · University Of California Berkeley · P42 · FY2009 · ES

Development of a first-in-class mEGFR dimerization inhibitor

$410,837
Mukesh K. Nyati · University Of Michigan At Ann Arbor · R01 · FY2023 · CA

Development of a first-in-class mEGFR dimerization inhibitor

$410,837
Mukesh K. Nyati · University Of Michigan At Ann Arbor · R01 · FY2022 · CA

Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance

$410,835
Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

Dissecting KRAS oncoprotein signaling with allele specific inhibitors

$410,835
Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance

$410,835
Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA

C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance

$410,835
Richard N Kolesnick · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Dissecting KRAS oncoprotein signaling with allele specific inhibitors

$410,835
Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA